Blood Research

Cited by CrossRef (6)

  1. Sudhir Kumar, Atul Sharma, Prabhat Singh Malik, Ajay Gogia, Neha Pathak, Ranjit Kumar Sahoo, Ritu Gupta, Chandra Prakash Prasad, Lalit Kumar. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial. Br J Haematol 2022;198:288
    https://doi.org/10.1111/bjh.18200
  2. Darren Pan, Joshua Richter. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody. CMAR 2023;Volume 15:741
    https://doi.org/10.2147/CMAR.S372237
  3. Scott R. Goldsmith, Mark A. Fiala, Brandon Wang, Mark A. Schroeder, Tanya M. Wildes, Armin Ghobadi, Keith Stockerl-Goldstein, Ravi Vij. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Ann Hematol 2020;99:1041
    https://doi.org/10.1007/s00277-020-03970-2
  4. Ji Hyun Lee, Sung-Hyun Kim. Treatment of relapsed and refractory multiple myeloma. Blood Res 2020;55:S43
    https://doi.org/10.5045/br.2020.S008
  5. Seung-Shin Lee, Je-Jung Lee. Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma. Chonnam Med J 2019;55:25
    https://doi.org/10.4068/cmj.2019.55.1.25
  6. Norbert Grzasko, Grzegorz Charlinski, Marta Morawska, Pawel Kicinski, Anna Waszczuk-Gajda, Joanna Drozd-Sokolowska, Edyta Subocz, Danuta Blonska, Malgorzata Razny, Agnieszka Druzd-Sitek, Jadwiga Holojda, Alina Swiderska, Lidia Usnarska-Zubkiewicz, Anna Masternak, Krzysztof Giannopoulos. Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. JCM 2021;10:5504
    https://doi.org/10.3390/jcm10235504
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd